CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Regulators have also imposed $160,000 in fines on Cigna's Express Scripts unit; $66,000 in fines on Rightway PBM Services; ...

Since taking office, President Donald Trump has brusquely removed a number of top officials from their positions, including a ...

Hundreds of pharmacies across Pennsylvania have gone out of business in recent years, data obtained by Spotlight PA show, and pharmacists say legislation passed last year to help isn’t doing ...

A coalition of religious groups, treasurers from Ohio, Texas, Nevada and Utah had contacted the retailer last year requesting ...

A judge has rejected $266 million awarded to Baltimore City by a jury in an opioid lawsuit against two pharmaceutical companies.

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Alleging that it was the true “architect” of West Virginia’s substance use disorder crisis first fueled by prescription ...

Alleging that it was the true “architect” of West Virginia’s substance use disorder crisis first fueled by prescription ...

Accusations have been exchanged by two prominent councillors as the fall out from a 'farcical' July meeting continues ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...